Skip to product information
1 of 1




Regular price €12,80 EUR
Regular price Sale price €12,80 EUR
Sale Sold out
Tax included. Shipping calculated at checkout.
Logo Farmaci da banco







View full details

Allergic conjunctivitis


Therapeutic indications

Allergic conjunctivitis.

Dosage and method of use

Posology Adults and children : the usual dose is 1 drop of LEVOREACT OPTHALMIC per eye, 2 times a day. The dose can be increased to 1 drop up to 3 or 4 times a day. Treatment should be continued for as long as symptoms disappear. Method of administration Ophthalmic use. For instructions on the use and handling of the medicinal product before administration, see section 6.6.


Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Side effects

Adverse drug reactions identified during clinical and epidemiological studies and from postmarketing experience following the use of LEVOREACT OPTHALMIC are listed in Table 1 ; frequencies are reported according to the following conventional classification: Very common ≥1/10 Common ≥1/100 and <1/10 Uncommon ≥1/1000 and <1/100 Rare ≥1/10,000 and <1/1000 Very rare < 1/10,000 Not known Frequency cannot be estimated from the available data Table 1: Adverse drug reactions identified during clinical trials and postmarketing experience with LEVOREACT OPHTHALMIC.

Heart pathologies
Not known Palpitations
Pathologies of the eye
Common Eye pain, blurred vision;
Uncommon Eyelid edema;
Not known Conjunctivitis, eye swelling, blepharitis, ocular hyperaemia.
General disorders and administration site conditions
Common Application site reaction, including burning/irritant sensation in the eyes, eye irritation.
Very rare Application site reaction, such as eye redness, itchy eyes.
Not known Application site reaction, such as lacrimation.
Immune system disorders
Not known Angioedema, hypersensitivity, anaphylactic reaction.
Skin and subcutaneous tissue disorders
Not known Contact dermatitis, urticaria.
Pathologies of the nervous system
Common Headache.

Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at

Special warnings

As with all ophthalmic preparations containing benzalkonium chloride, propylene glycol and esters, patients should be advised not to use soft (hydrophilic) contact lenses during treatment with LEVOREACT OPHTHALMIC eye drops suspension as they may cause eye irritation. Remove contact lenses before applying the medicine and wait at least 15 minutes before putting them back on. The medicine discolours soft contact lenses.

Pregnancy and breastfeeding

Pregnancy Studies in animals have not shown embryotoxic or teratogenic effects (see section 5.3). There is limited postmarketing data from the use of levocabastine eye drops, suspension in pregnant women; the risk for humans is not known, therefore LEVOREACT OPTHALMIC should not be used during pregnancy, unless the potential benefit to the woman justifies the potential risk to the foetus. Breast-feeding Based on concentration determinations of levocabastine in saliva and breast milk from a nursing woman given a single oral dose of 0.5 mg levocabastine, approximately 0.3% of the dose would be expected to amount of levocabastine administered ophthalmologically, can be transmitted to the infant. However, due to the limited availability of clinical and experimental data, caution is recommended when administering LEVOREACT OPTHALMIC to breastfeeding women. Fertility Animal data have shown no effect on male or female fertility (see section 5.3).

Expiration and conservation

Do not store above 25°C.

Interactions with other drugs

No interaction studies have been performed.


Symptoms No cases of overdose with LEVOREACT OPTHALMIC have been reported. However, the occurrence of sedation after accidental ingestion of the vial contents cannot be excluded. Treatment In case of accidental ingestion, advise the patient to drink plenty of non-alcoholic liquids in order to accelerate the renal elimination of levocabastine.

Active principles

One ml of eye drops, suspension contains: levocabastine hydrochloride 0.54 mg (equivalent to 0.5 mg of levocabastine). Excipients with known effect: propylene glycol, benzalkonium chloride. For the full list of excipients, see section 6.1.


Propylene glycol, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate anhydrous, hydroxypropyl methylcellulose 2910, polysorbate 80, benzalkonium chloride, disodium edetate, water for injections.



    Shipping in Italy 24/48H
    Delivery also on Saturday and Sunday
    Free over €49.90

    Shipping in Europe 24/72H
    Free over €80

    Shipping to UK 24/72H
    Free over €150


    The security of your data matters to us!

    We are fully compliant with the European GDPR regarding Privacy and Processing of personal data.

    Payments you make on our site are 100% safe and guaranteed.


    Fast returns through do-it-yourself portal and 14 days to reconsider.

    Fast and free replacements for incorrect or non-compliant products delivered.